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Abstract
Background:  Current data on incidence of interstitial lung diseases (ILDs) are sparse and
concerns about an increasing trend have been raised. We examined incidence rates (IRs) of ILDs
and changes in IRs between 1995 and 2005.
Methods: All persons with a first-time hospital discharge or outpatient diagnosis of ILD were
identified through the Danish National Registry of Patients, which covers all Danish hospitals.
Crude and age-standardised IRs were computed for ILD overall, as well as stratified by ILD
subcategories.
Results: A total of 21,765 patients with ILD were identified. Between 1995 and 1998 the overall
standardised IR of ILD decreased from 27.14 (95% CI 25.82–28.46) per 100,000 person-years to
19.36 (95% CI 18.26–20.46) per 100,000 person-years. After 1998 the IR increased considerably,
peaking at 34.34 (95% CI 32.84–35.85) per 100,000 person-years in 2002. Subsequently there was
a slight decrease. The highest IR was observed in the non-specific category "Respiratory disorders
in diseases classified elsewhere". By ILD subcategory, the greatest average increase during the study
period was observed in "Respiratory disorders in diseases classified elsewhere".
Conclusion: The incidence rate of ILD in Denmark increased during the study period, most
pronounced for ILDs associated with systemic diseases.
Background
Interstitial lung diseases (ILDs) are a heterogeneous group
of more than 200 different serious disease entities with
common functional characteristics such as restrictive
physiology and impaired gas exchange, and with variable
degrees of pulmonary inflammation and fibrosis [1,2].
Approximately two-thirds of ILD cases have no reported
aetiology [3]. The remaining one-third is associated with
or defined by various environmental or occupational fac-
tors including cigarette smoking, aspiration, certain drugs,
radiation therapy, cancer, and systemic diseases with lung
involvement [2-4].
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Data on the incidence of ILDs are sparse [2,4]. The few
previous studies have reported an eightfold variation in
ILD incidence, from 3.62 per 100,000 person-years in
southern Spain [5] to 31.5 per 100,000 person-years in
males and 26.1 per 100,000 person-years in females in
New Mexico, USA [6]. The inconsistency of estimated inci-
dence rates internationally may stem from differences in
sampling procedures and diagnostic criteria and measure-
ment bias arising from variation in coding practices and
case ascertainment. Previous European studies of ILD
occurrence, based on questionnaires sent to chest physi-
cians, may underestimate the true incidence [5,7-10]. The
only truly population-based study, conducted over 15
years ago, encompassed a relatively small US population
of 480,577 and was restricted to a 2-year study period [6].
While some reports suggest that the prevalence and inci-
dence of ILDs have increased during recent decades [3],
no population-based longitudinal studies have docu-
mented recent temporal trends in ILD subgroups.
Updated incidence data are essential for predicting health
care demand, for evaluating continuing needs for preven-
tion programs such as asbestosis abatement, and to foster
our understanding of possible changes in presumed risk
factors over time.
We conducted this population-based study to examine the
current incidence rate of ILDs and temporal changes in
incidence rate between 1995 and 2005.
Methods
Setting and study population
The entire Danish population of 5.4 million people was
setting for this population-based study [11]. The Danish
National Health Service provides tax-supported health
care for all residents, including free access to primary care
and hospitals. Care of all patients with complicated respi-
ratory diseases, including ILDs, is provided by specialised
centres within public hospitals operating under the aus-
pices of the Danish National Health Service. Since 1968,
the Danish Civil Registration System has kept electronic
records, updated daily, on date of birth, gender, change of
address, date of emigration, and changes in vital status for
all Danish residents. Use of civil registration numbers,
assigned to every Danish resident, allows accurate linkage
among Danish registries [11].
Identification of patients with interstitial lung disease
The Danish National Registry of Patients (NRP) contains
information on all discharges from non-psychiatric hospi-
tals since 1977. Information on outpatient and emergency
room visits was added in 1995. The NRP includes civil reg-
istration number, dates of hospital admission and dis-
charge, and up to 20 discharge diagnoses, classified by
physicians according to the International Classification of
Diseases, 8th revision (ICD-8) until the end of 1993 and
according to the 10th revision (ICD-10) thereafter. We
included all patients with a first-time hospital discharge or
hospital outpatient visit diagnosis of ILD between 1 Janu-
ary, 1995 and 31 December, 2005. We included ILD diag-
noses registered as either primary or secondary diagnosis
in the hospital discharge list. The following ICD-10 codes
were used: J60.X–J70.X (except J66, J68.2, J70.8, and
J70.9), J82.X, J84.X, J99.X, D76.0, D86.0 and D86.2. (See
additional file 1 for further information on ICD codes).
Since we were interested in the incidence of ILD, we
excluded patients diagnosed with ILD in 1994.
Statistical analysis
We computed annual crude and age-standardised inci-
dence rates (IRs) for ILD overall and stratified by gender.
IRs were defined as the number of patients with a first-
time diagnosis of ILD in a given year divided by the
number of citizens alive in Denmark in the middle of that
year (obtained from Statistics Denmark). Age-standard-
ised IRs were computed based on the 2000 world popula-
tion (age groups: 0–14 years, 15–39 years, 40–64 years,
65–79 years, and 80+ years).
We divided the 10-year study into two periods (1 January,
1995 – 31 December, 2000 and 1 January, 2001 – 31
December, 2005) and defined IRs as the number of
patients with a first time diagnosis of ILD in each time
period divided by the total number of citizens alive in
Denmark in the middle of each calendar year band. This
approach was used overall and within subcategories of
ICD-10 codes, as well as for gender- and age-specific
strata. We then computed age-standardised rates for over-
all ILDs, gender, and subcategories of ILDs, standardised
to the 2000 world population.
Statistical analyses were performed with SAS software
(version 9.1.3; SAS Institute, Cary, NC). The study was
approved by the Danish Data Protection Agency (Record
no. 2005-41-5511). No ethics approval was required
because no primary data collection was done.
Results
Overall incidence
Between 1995 and 2005, 21,765 patients were registered
with a first-time discharge or outpatient diagnosis of ILD.
The median age of the 12,639 (58%) men was 63 years
(interquartile range 44–75 years) and that of the 9,126
(42%) women was 64 years (interquartile range 45–76
years).
Figure 1 shows the annual standardised IRs of ILD.
Between 1995 and 1998 the overall standardised IR of ILD
decreased from 27.14 (95% CI 25.82–28.46) per 100,000BMC Pulmonary Medicine 2008, 8:24 http://www.biomedcentral.com/1471-2466/8/24
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person-years to 19.36 (95% CI 18.26–20.46) per 100,000
person-years. After 1998 the IR increased considerably,
peaking at 34.34 (95% CI 32.84–35.85) per 100,000 per-
son-years in 2002. Subsequently there was a slight
decrease.
The age-standardised IR increased from 23.54 (95% CI
23.04–24.04) per 100,000 person-years in 1995–2000 to
31.28 (95% CI 30.64–31.92) per 100,000 person-years in
2001–2005 (Table 1). The IR of ILDs increased with
increasing age, from 18.90 (95% CI 18.00–19.80) per
100,000 person-years in those aged 15–39 years to 165.41
(95% CI 157.73–173.08) per 100,000 person-years in
those aged ≥80 years. Age-standardised incidence rates of
ILDs were approximately 50% higher in males than in
females throughout the study period.
Incidence of specific ILD diagnoses
In the 2001–2005 period, ILD subcategories with the
highest IRs were "Respiratory disorders in diseases classi-
fied elsewhere" (standardised IR 7.73; 95% CI 7.39–
8.07), "Other interstitial pulmonary diseases except idio-
pathic pulmonary fibrosis" (standardised IR 6.26; 95% CI
6.00–6.52), "Pneumonitis due to solids and liquids"
(standardised IR 5.20; 95% CI 4.92–5.47) and "Sarcoido-
sis with lung involvement" (standardised IR 4.11; 95% CI
Standardised incidence rates of ILD overall and by gender Figure 1
Standardised incidence rates of ILD overall and by gender. Denmark 1995–2005. Age-standardised to the 2000 world 
population.BMC Pulmonary Medicine 2008, 8:24 http://www.biomedcentral.com/1471-2466/8/24
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3.87–4.34) (Table 2). The highest average increase in inci-
dence between 1995–2000 and 2001–2005 was in the
subcategory J99 "Respiratory disorders in diseases classi-
fied elsewhere" (Table 2 and 3). The IR for each subcate-
gory of J99 ("J99.0 Rheumatoid lung disease", "J99.1
Respiratory disorders in other diffuse connective tissue
disorders" and "J99.8 Respiratory disorders in other dis-
eases classified elsewhere") is also shown in table 2 and 3.
Of the 3,152 patients with a J99 diagnosis, 862 were
coded with a subcategory of J99. A decrease in incidence
between the two periods was found only in the following
subcategories: "pneumoconiosis due to asbestos and
other mineral fibres, dust containing silica, and other
inorganic dust", "unspecified pneumoconiosis", "pulmo-
nary eosinophilia", "idiopathic pulmonary fibrosis".
Discussion
In this large population-based study conducted within a
well-defined Northern European population, the overall
IR of ILDs was around 31 per 100,000 person-years in
2001–2005 and increased with 33% between 1995–2000
and 2001–2005. The increased incidence was observed in
all age groups and in both genders. The increase was most
noticeable in ILDs associated with other systemic diseases.
The study's longitudinal population-based design, based
on data from the free tax-supported Danish health care
system, enabled us to identify all hospital discharge and
outpatient diagnoses of ILDs during a 10-year period, and
limited the risk of referral and diagnostic bias. The validity
of our findings depends ultimately on the accuracy of ILD
coding, including levels of diagnostic work-up, and com-
pleteness of reporting in the Danish National Registry of
Patients. A previous examination of the validity of diag-
noses of interstitial lung diseases caused by external
agents in the Danish National Registry of Patients yielded
high positive predictive values of 92% (95% CI: 73%–
98%) for drug induced ILDs and 87% (95% CI: 59%–
98%) for radiation induced ILDs, compared with other
discharge diagnoses [12,13]. The ICD-10 codes used to
identify cases in this study do not correspond completely
to the new classification recently developed for ILDs [14].
We thus were not able to apply the new classification to
data in the Danish National Registry of Patients.
We may have missed patients with ILD seen only by pri-
mary care physicians, causing an underestimation of the
true incidence. However, to explain the increasing inci-
dence of ILDs, the number of ILD patients treated by pri-
mary care physicians should have changed substantially
during the 10 year study period. This is an unlikely sce-
nario, particularly since the Danish National Board of
Health recommends that diagnosis and treatment of
patients with ILDs occur only at highly specialised
national centres [15]. While younger patients with ILD
may be more likely to be referred to a hospital for treat-
ment, controlling for age in the analysis limited the poten-
tial effect of this bias on our results.
We excluded patients registered with a diagnosis of ILD in
1994, to avoid including prevalent ILD cases. Still, we can-
not entirely exclude the possibility that a combination of
prevalent and incident cases might have been captured in
the beginning of the study period. This potentially could
lead to overestimation of ILD incidence in the beginning
of the study period and to underestimation of the increase
in incidence during the entire period and thus attenuate
the time trend changes.
The IR found in our study is almost ninefold higher than
that reported for previous European studies [5], perhaps
because the earlier studies may have been limited by
incomplete reporting restricted to chest physicians' diag-
noses [5,8]. Contrary, our results accord with those from
the 1994 population-based two-year cross sectional study
conducted by Coultas et al. in New Mexico [6] despite the
use of different case ascertainment methods and patients'
exposure to different environmental factors. In the New
Mexico study, patients with ILDs were identified from a
Table 1: The incidence (per 100,000 person-years) of ILD in 
Denmark overall and within age- and gender-specific strata
1995–2000 Cases
(N)
Incidence rates
Crude
(95% CI)*
Incidence rates
Age-standardised
(95% CI)*
Overall 10,318 32.57 (31.94–33.20) 23.54 (23.04–24.04)
Age
0–14 609 10.76 (9.91–11.62)
15–39 1,449 13.01 (12.34–13.68)
40–64 3,312 32.72 (31.61–33.84)
65–79 3,584 101.81 (98.48–105.15)
80+ 1,364 110.06 (104.21–115.90)
Gender
Male 6,063 38.75 (37.78–39.73) 29.12 (28.33–29.90)
Female 4,255 26.54 (25.74–27.33) 18.69 (18.05–19.33)
2001–2005
Overall 11,447 42.66 (41.88–43.44) 31.28 (30.64–31.92)
Age
0–14 815 16.23 (15.12–17.35)
15–39 1,693 18.90 (18.00–19.80)
40–64 3,737 42.08 (40.74–43.43)
65–79 3,418 118.02 (114.07–121.98)
80+ 1,784 165.41 (157.73–173.08)
Gender
Male 6,576 49.56 (48.36–50.76) 37.79 (36.81–38.78)
Female 4,871 35.90 (34.90–36.91) 25.43 (24.61–26.25)
*CI: confidence intervalBMC Pulmonary Medicine 2008, 8:24 http://www.biomedcentral.com/1471-2466/8/24
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Table 2: Crude and age-standardized incidence (per 100,000 persons-years) within subcategories of ILD in Denmark 2001–2005
Subcategories and diseases ICD code Cases (N) Incidence rates
Crude
(95% CI)*
Incidence rates
Age-standardised
(95% CI)*
Coalworkers' pneumoconiosis J60 17 0.06 (0.03–0.09) 0.05 (0.03–0.08)
Pneumoconiosis due to asbestos and other mineral fibres J61 332 1.24 (1.10–1.37) 0.70 (0.62–0.78)
Pneumoconiosis due to dust containing silica J62 53 0.20 (0.14–0.25) 0.14 (0.10–0.18)
Pneumoconiosis due to other inorganic dusts J63 29 0.11 (0.07–0.15) 0.07 (0.04–0.10)
Unspecified pneumoconiosis J64 173 0.64 (0.55–0.74) 0.36 (0.30–0.42)
Pneumoconiosis associated with tuberculosis J65 18 0.07 (0.04–0.10) 0.08 (0.04–0.12)
Hypersensitivity pneumonitis due to organic dust J67 213 0.79 (0.69–0.90) 0.70 (0.60–0.80)
Respiratory conditions due to inhalation of chemicals, gases, 
fumes and vapours
J68 (except J68.2) 519 1.93 (1.77–2.10) 1.80 (1.64–1.97)
Pneumonitis due to solids and liquids J69 1,915 7.14 (6.82–7.46) 5.20 (4.92–5.47)
Respiratory conditions due to other external agents J70 (except J70.8, J70.9) 191 0.71 (0.61–0.81) 0.43 (0.37–0.50)
Pulmonary eosinophilia, not elsewhere classified J82 161 0.60 (0.51–0.69) 0.39 (0.32–0.45)
Idiopathic pulmonary fibrosis J84.1 1,417 5.28 (5.01–5.56) 2.91 (2.75–3.08)
Other interstitial pulmonary diseases except idiopathic 
pulmonary fibrosis
J84 (except J84.1) 2,619 9.76 (9.39–10.13) 6.26 (6.00–6.52)
Respiratory disorders in diseases classified elsewhere J99 2,461 9.17 (8.81–9.53) 7.73 (7.39–8.07)
Rheumatoid lung disease J99.0 21 0.08 (0.04–0.11) 0.06 (0.03–0.09)
Respiratory disorders in other diffuse connective tissue 
disorders
J99.1 46 0.17 (0.12–0.22) 0.12 (0.08–0.16)
Respiratory disorders in other diseases classified elsewhere J99.8 705 2.63 (2.43–2.82) 2.27 (2.09–2.46)
Langerhans'cell histiocytosis D76.0 72 0.27 (0.21–0.33) 0.35 (0.27–0.44)
Sarcoidosis with lung involvement D86.0 orD86.2 1,257 4.68 (4.43–4.94) 4.11 (3.87–4.34)
*CI: confidence interval
Table 3: Crude and age-standardized incidence (per 100,000 persons-years) within subcategories of ILD in Denmark 1995–2000
Subcategories
and diseases
ICD code Cases
(N)
Incidence 
rates Crude
(95% CI)*
Incidence rates
Age-standardised
(95% CI)*
Coalworkers' pneumoconiosis J60 7 0.02 (0.01–0.04) 0.02 (0.00–0.03)
Pneumoconiosis due to asbestos and other mineral fibres J61 540 1.70 (1.56–1.85) 1.01 (0.92–1.09)
Pneumoconiosis due to dust containing silica J62 116 0.37 (0.30–0.43) 0.24 (0.19–0.29)
Pneumoconiosis due to other inorganic dusts J63 45 0.14 (0.10–0.18) 0.10 (0.07–0.13)
Unspecified pneumoconiosis J64 229 0.72 (0.63–0.82) 0.41 (0.35–0.47)
Pneumoconiosis associated with tuberculosis J65 13 0.04 (0.02–0.06) 0.05 (0.02–0.08)
Hypersensitivity pneumonitis due to organic dust J67 255 0.80 (0.71–0.90) 0.68 (0.59–0.77)
Respiratory conditions due to inhalation of chemicals, gases, fumes and 
vapours
J68 (except J68.2) 549 1.73 (1.59–1.88) 1.62 (1.48–1.77)
Pneumonitis due to solids and liquids J69 1,449 4.57 (4.34–4.81) 3.86 (3.63–4.10)
Respiratory conditions due to other external agents J70 (except J70.8, J70.9) 174 0.55 (0.47–0.63) 0.38 (0.32–0.45)
Pulmonary eosinophilia, not elsewhere classified J82 299 0.94 (0.84–1.05) 0.63 (0.56–0.71)
Idiopathic pulmonary fibrosis J84.1 2,303 7.27 (6.97–7.57) 4.17 (3.99–4.36)
Other interstitial pulmonary diseases except idiopathic pulmonary 
fibrosis
J84
(except J84.1)
2,374 7.49 (7.19–7.80) 4.89 (4.68–5.10)
Respiratory disorders in diseases classified elsewhere J99 691 2.18 (2.02–2.34) 1.83 (1.68–1.99)
Rheumatoid lung disease J99.0 4 0.01 (0.00–0.02) 0.01 (0.00–0.02)
Respiratory disorders in other diffuse connective tissue disorders J99.1 20 0.06 (0.04–0.09) 0.05 (0.03–0.08)
Respiratory disorders in other diseases classified elsewhere J99.8 66 0.21 (0.16–0.26) 0.19 (0.14–0.24)
Langerhans'cell histiocytosis D76.0 85 0.27 (0.21–0.33) 0.37 (0.29–0.45)
Sarcoidosis with lung involvement D86.0 or D86.2 1,189 3.75 (3.54–3.97) 3.27 (3.08–3.46)
*CI: confidence intervalBMC Pulmonary Medicine 2008, 8:24 http://www.biomedcentral.com/1471-2466/8/24
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number of sources: hospital diagnoses, physician refer-
rals, histopathology reports, and death certificates.
Our study is the first to report recent 10-year time trends
for ILD subgroups in a defined population. Our findings
of a slightly decreased incidence rate of idiopathic pulmo-
nary fibrosis is in contrast to two recent US studies report-
ing an increased incidence and mortality from idiopathic
pulmonary fibrosis [16,17]. This discrepancy could in part
be due to geographic variations but also to differences in
data collection methods. Based on death certificates diag-
noses, classified according to ICD-9 until the end of 1998
and according to ICD-10 thereafter, Olson et al. found
increasing mortality rates from pulmonary fibrosis
between 1992 and 2003 [16]. They were, however not
able to determine, whether this increase at least in part
could be explained by differences in coding during the
study period. Using a national health care claims database
Raghu et al. found that idiopathic pulmonary fibrosis is
more common than previous reported but no time trends
were presented [17]. In our study, although using the
same coding system throughout the study period, we can
not entirely exclude the possibility that there may have
been changes in coding of diagnoses with a shift from idi-
opathic pulmonary fibrosis (J84.1) to more disease spe-
cific codes."
The rising overall incidence of ILDs could reflect a causal
rise, but the use of new and more sensitive diagnostic
methods, such as high-resolution CT-scans may have con-
tributed to the rise [3]. In Denmark the number of CT-
scans increased during the study period, which may have
increased the likelihood of diagnosing mild ILD cases and
thus could explain some of the observed rising incidence
rate of ILD. Still, the increased use of CT-scans would
most likely primarily have influenced diseases classifica-
tion. However, the large group of unclassified patients
with ILDs both in earlier and later years of the study
period argues against major diagnostic improvements
over time. Finally, the coding practice may have become
more meticulous during the last decade due to more focus
on ILD.
Some of the observed changes in subgroups are of inter-
ests. The observed predominance of ILD among male
patients has previously been described [5,6,9]. It could
stem from higher occupational exposure to risk factors [9]
or to higher smoking frequency among men. Among ILD
subcategories, the highest average increase in incidence
was observed in the non-specific category "Respiratory
disorders in diseases classified elsewhere". This category
includes, however, not only rheumatoid lung disease and
ILD associated with diffuse connective tissue disorders but
also respiratory disorders in infections and other illnesses.
Decreased ILD incidence for most subcategories of pneu-
moconiosis may reflect reduced use of asbestosis products
and safer working environments.
Conclusion
In conclusion, we found a higher incidence of ILD than
reported in previous European studies [5]. The overall IR
of ILD showed a clear increase between 1995–2000 and
2001–2005, in particular for ILDs associated with other
systemic diseases. These findings underscore the need for
improved primary prevention efforts to reduce risk factors
associated with ILD.
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